======= JARID2 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: JARID2
  * **<color #00a2e8>Official Name</color>**: jumonji and AT-rich interaction domain containing 2
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=3720|3720]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q92833|Q92833]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=JARID2&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20JARID2|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/601594|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**: N/A
  * **<color #00a2e8>UniProt Summary</color>**:  Regulator of histone methyltransferase complexes that plays an essential role in embryonic development, including heart and liver development, neural tube fusion process and hematopoiesis. Acts by modulating histone methyltransferase activity and promoting the recruitment of histone methyltransferase complexes to their target genes. Binds DNA and mediates the recruitment of the PRC2 complex to target genes in embryonic stem cells. Does not have histone demethylase activity but regulates activity of various histone methyltransferase complexes. In embryonic stem cells, it associates with the PRC2 complex and inhibits trimethylation of 'Lys-27' of histone H3 (H3K27me3) by the PRC2 complex, thereby playing a key role in differentiation of embryonic stem cells and normal development. In cardiac cells, it is required to repress expression of cyclin-D1 (CCND1) by activating methylation of 'Lys-9' of histone H3 (H3K9me) by the GLP1/EHMT1 and G9a/EHMT2 histone methyltransferases. Also acts as a transcriptional repressor of ANF via its interaction with GATA4 and NKX2-5. Participates in the negative regulation of cell proliferation signaling. {ECO:0000269|PubMed:20075857}.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|JmjN|
|zf-C5HC2|
|JmjC|
|ARID|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|histone demethylase activity (H3-trimethyl-K4 specific)|
|histone H3-K4 demethylation, trimethyl-H3-K4-specific|
|histone H3-K4 demethylation|
|positive regulation of histone H3-K9 methylation|
|negative regulation of cardiac muscle cell proliferation|
|histone demethylase activity|
|ESC/E(Z) complex|
|negative regulation of histone methylation|
|regulation of histone H3-K9 methylation|
|negative regulation of heart growth|
|negative regulation of cardiac muscle tissue growth|
|negative regulation of cardiac muscle hypertrophy|
|histone lysine demethylation|
|negative regulation of muscle hypertrophy|
|histone demethylation|
|protein demethylation|
|protein dealkylation|
|negative regulation of organ growth|
|negative regulation of cardiac muscle tissue development|
|spleen development|
|positive regulation of histone methylation|
|regulation of cardiac muscle cell proliferation|
|negative regulation of histone modification|
|histone methyltransferase complex|
|thymus development|
|negative regulation of striated muscle tissue development|
|negative regulation of muscle organ development|
|negative regulation of muscle tissue development|
|regulation of cardiac muscle hypertrophy|
|regulation of cardiac muscle tissue growth|
|regulation of muscle hypertrophy|
|negative regulation of chromatin organization|
|regulation of heart growth|
|demethylation|
|regulation of histone methylation|
|regulation of cardiac muscle tissue development|
|negative regulation of gene expression, epigenetic|
|regulation of muscle adaptation|
|positive regulation of histone modification|
|regulation of organ growth|
|response to leukemia inhibitory factor|
|cellular response to leukemia inhibitory factor|
|positive regulation of chromatin organization|
|negative regulation of developmental growth|
|liver development|
|hepaticobiliary system development|
|regulation of striated muscle tissue development|
|negative regulation of chromosome organization|
|regulation of muscle tissue development|
|regulation of muscle organ development|
|regulation of histone modification|
|stem cell differentiation|
|chromatin remodeling|
|positive regulation of chromosome organization|
|regulation of chromatin organization|
|regulation of muscle system process|
|regulation of gene expression, epigenetic|
|negative regulation of growth|
|DNA-binding transcription repressor activity, RNA polymerase II-specific|
|RNA polymerase II regulatory region sequence-specific DNA binding|
|regulation of developmental growth|
|transcription factor binding|
|regulation of chromosome organization|
|histone modification|
|negative regulation of organelle organization|
|covalent chromatin modification|
|chromatin binding|
|gland development|
|regulation of system process|
|negative regulation of protein modification process|
|hematopoietic or lymphoid organ development|
|positive regulation of organelle organization|
|immune system development|
|regulation of growth|
|negative regulation of cell population proliferation|
|chromatin organization|
|negative regulation of cellular component organization|
|negative regulation of transcription by RNA polymerase II|
|negative regulation of developmental process|
|central nervous system development|
|cellular response to cytokine stimulus|
|negative regulation of cellular protein metabolic process|
|chromosome organization|
|response to cytokine|
|negative regulation of protein metabolic process|
|negative regulation of transcription, DNA-templated|
|negative regulation of multicellular organismal process|
|positive regulation of cellular component organization|
|positive regulation of protein modification process|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|mitochondrion|
|regulation of organelle organization|
|negative regulation of RNA metabolic process|
|negative regulation of cellular macromolecule biosynthetic process|
|negative regulation of nucleobase-containing compound metabolic process|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|negative regulation of biosynthetic process|
|DNA-binding transcription factor activity, RNA polymerase II-specific|
|positive regulation of cellular protein metabolic process|
|regulation of cell population proliferation|
|positive regulation of protein metabolic process|
|negative regulation of gene expression|
|regulation of protein modification process|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='default' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp292|Menadione 5μM R06 exp292]]|-2.04|
|[[:results:exp340|BN82002 4μM R07 exp340]]|-1.73|
|[[:results:exp330|5-Azacytidine 2μM R07 exp330]]|-1.71|
|[[:results:exp214|2-Deoxy-D-glucose 800μM R05 exp214]]|1.77|
|[[:results:exp248|UM0131023 0.05μM R05 exp248]]|1.79|
|[[:results:exp352|Dexamethasone 0.006 to 0.015μM on day4 R07 exp352]]|2.25|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
No correlation found to any other genes in chemogenomics.
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 0/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/25|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/15|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/14|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 12633
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 6.09 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='JARID2 Expression in NALM6 Cells: 6.09'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>